A Phase I Study of Immunotherapy with Genetically Modified T Cells to Treat Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma

Full Title

A Phase 1, Multicenter, Open-label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

Purpose

The purpose of this study is to evaluate the safety of an investigational treatment for people with diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or mantle cell lymphoma that has continued to grow or came back despite prior therapy. The treatment involves removing some of a patient's immune cells called T cells, genetically modifying and growing them in a laboratory, and then returning them to the patient to find and kill lymphoma cells.

The new modified T cells are called JCAR017 cells and are given back to the patient intravenously (by vein). This approach is a form of immunotherapy.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or mantle cell lymphoma that has continued to grow or came back despite prior therapy.
  • Patients must recover from the serious side effects of previous treatments before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. M. Lia Palomba at 212-639-7186.

Protocol

15-295

Phase

I

Investigator

Co-Investigators

Locations